Yuanyuan Liu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6144475/publications.pdf

Version: 2024-02-01

		218677	243625
65	2,159	26	44
papers	citations	h-index	g-index

69	69	69	2486
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficient mucus permeation and tight junction opening by dissociable â€œmucus-inertâ€•agent coated trimethyl chitosan nanoparticles for oral insulin delivery. Journal of Controlled Release, 2016, 222, 67-77.	9.9	210
2	Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting. Biomaterials, 2014, 35, 5171-5187.	11.4	120
3	Multistage Nanovehicle Delivery System Based on Stepwise Size Reduction and Charge Reversal for Programmed Nuclear Targeting of Systemically Administered Anticancer Drugs. Advanced Functional Materials, 2015, 25, 4101-4113.	14.9	118
4	Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery. ACS Applied Materials & Interfaces, 2018, 10, 9916-9928.	8.0	113
5	Chondroitin Sulfate-Linked Prodrug Nanoparticles Target the Golgi Apparatus for Cancer Metastasis Treatment. ACS Nano, 2019, 13, 9386-9396.	14.6	107
6	Novel Solid Lipid Nanoparticle with Endosomal Escape Function for Oral Delivery of Insulin. ACS Applied Materials & Interfaces, 2018, 10, 9315-9324.	8.0	93
7	A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. Biomaterials, 2015, 65, 43-55.	11.4	85
8	Linear Chimeric Triblock Molecules Selfâ€Assembled Micelles with Controllably Transformable Property to Enhance Tumor Retention for Chemoâ€Photodynamic Therapy of Breast Cancer. Advanced Functional Materials, 2019, 29, 1808462.	14.9	76
9	Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin. International Journal of Pharmaceutics, 2015, 496, 993-1005.	5.2	61
10	Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. Acta Pharmaceutica Sinica B, 2019, 9, 615-625.	12.0	61
11	Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs. Journal of Controlled Release, 2017, 262, 273-283.	9.9	58
12	Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. Biomaterials, 2021, 273, 120847.	11.4	55
13	Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis. Biomaterials, 2020, 258, 120296.	11.4	52
14	Dual Stimuli-Responsive Hybrid Polymeric Nanoparticles Self-Assembled from POSS-Based Starlike Copolymer-Drug Conjugates for Efficient Intracellular Delivery of Hydrophobic Drugs. ACS Applied Materials & Interfaces, 2016, 8, 13251-13261.	8.0	51
15	Self-propelled nanomotor reconstructs tumor microenvironment through synergistic hypoxia alleviation and glycolysis inhibition for promoted anti-metastasis. Acta Pharmaceutica Sinica B, 2021, 11, 2924-2936.	12.0	47
16	The combination of endolysosomal escape and basolateral stimulation to overcome the difficulties of â€œeasy uptake hard transcytosisâ€•of ligand-modified nanoparticles in oral drug delivery. Nanoscale, 2018, 10, 1494-1507.	5.6	44
17	The transport mechanism of integrin Î± v Î² 3 receptor targeting nanoparticles in Caco-2 cells. International Journal of Pharmaceutics, 2016, 500, 42-53.	5.2	38
18	A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression. Journal of Controlled Release, 2020, 325, 38-51.	9.9	38

#	Article	IF	Citations
19	A pH-responsive sequential-disassembly nanohybrid for mitochondrial targeting. Nanoscale, 2017, 9, 314-325.	5.6	37
20	Milk-derived exosomes exhibit versatile effects for improved oral drug delivery. Acta Pharmaceutica Sinica B, 2022, 12, 2029-2042.	12.0	35
21	Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance. Biomacromolecules, 2019, 20, 3755-3766.	5.4	34
22	Mitochondrial targeted strategies and their application for cancer and other diseases treatment. Journal of Pharmaceutical Investigation, 2020, 50, 271-293.	5.3	34
23	Time-staggered delivery of docetaxel and H1-S6A,F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting. Journal of Controlled Release, 2016, 232, 62-74.	9.9	31
24	Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer. ACS Applied Materials & Interfaces, 2020, 12, 1606-1616.	8.0	30
25	Nanoprobe-Based Magnetic Resonance Imaging of Hypoxia Predicts Responses to Radiotherapy, Immunotherapy, and Sensitizing Treatments in Pancreatic Tumors. ACS Nano, 2021, 15, 13526-13538.	14.6	30
26	Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis. ACS Nano, 2022, 16, 50-67.	14.6	29
27	Melanin-originated carbonaceous dots for triple negative breast cancer diagnosis by fluorescence and photoacoustic dual-mode imaging. Journal of Colloid and Interface Science, 2017, 497, 226-232.	9.4	27
28	Charge-Reversible Multifunctional HPMA Copolymers for Mitochondrial Targeting. ACS Applied Materials & Interfaces, 2017, 9, 27563-27574.	8.0	27
29	Transport Mechanisms of Butyrate Modified Nanoparticles: Insight into â€œEasy Entry, Hard Transcytosisâ€•of Active Targeting System in Oral Administration. Molecular Pharmaceutics, 2018, 15, 4273-4283.	4.6	27
30	Dual-sensitive and biodegradable core-crosslinked HPMA copolymerâ€“doxorubicin conjugate-based nanoparticles for cancer therapy. Polymer Chemistry, 2017, 8, 2370-2380.	3.9	25
31	Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Antiâ€PDâ€L1 Therapy. Small, 2022, 18, e2104591.	10.0	23
32	Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade. Journal of Controlled Release, 2021, 334, 248-262.	9.9	22
33	Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade. Acta Pharmaceutica Sinica B, 2022, 12, 2533-2549.	12.0	22
34	Programmed drug delivery system based on optimized â€œsize decrease and hydrophilicity/hydrophobicity transformationâ€•for enhanced hepatocellular carcinoma therapy of doxorubicin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1111-1122.	3.3	18
35	Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2. International Journal of Pharmaceutics, 2018, 551, 14-22.	5.2	18
36	Sequentially Targeting Cancerâ€Associated Fibroblast and Mitochondria Alleviates Tumor Hypoxia and Inhibits Cancer Metastasis by Preventing â€œSoilâ€•Formation and â€œSeedâ€•Dissemination. Advanced Functional Materials, 2021, 31, 2010283.	14.9	18

#	Article	IF	Citations
37	Chondroitin sulfate-based prodrug nanoparticles enhance photodynamic immunotherapy via Golgi apparatus targeting. Acta Biomaterialia, 2022, 146, 357-369.	8.3	17
38	Mitochondria-targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of Î±-tocopheryl succinate. Journal of Materials Chemistry B, 2018, 6, 7674-7683.	5.8	16
39	Synthesis and characterization of HPMC derivatives as novel duodenum-specific coating agents. Archives of Pharmacal Research, 2005, 28, 364-369.	6.3	15
40	Coordination of rigidity modulation and targeting ligand modification on orally-delivered nanoparticles for the treatment of liver fibrosis. Journal of Controlled Release, 2022, 341, 215-226.	9.9	15
41	Nanoparticles with surface features of dendritic oligopeptides as potential oral drug delivery systems. Journal of Materials Chemistry B, 2020, 8, 2636-2649.	5.8	13
42	Promoting apical-to-basolateral unidirectional transport of nanoformulations by manipulating the nutrient-absorption pathway. Journal of Controlled Release, 2020, 323, 151-160.	9.9	13
43	Glymphatic System and Subsidiary Pathways Drive Nanoparticles Away from the Brain. Research, 2022, 2022, 9847612.	5.7	13
44	Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies. International Journal of Pharmaceutics, 2018, 536, 450-458.	5.2	11
45	Bioinspired Scalable Total Synthesis of Opioids. CCS Chemistry, 2021, 3, 1376-1383.	7.8	11
46	Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis. ACS Nano, 2022, 16, 6064-6079.	14.6	11
47	Stimuliâ€Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis. Advanced Materials Interfaces, 2021, 8, 2002200.	3.7	10
48	Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy. International Journal of Pharmaceutics, 2019, 570, 118668.	5.2	9
49	Angiopep-2-functionalized nanoparticles enhance transport of protein drugs across intestinal epithelia by self-regulation of targeted receptors. Biomaterials Science, 2021, 9, 2903-2916.	5.4	9
50	Concurrent impairment of nucleus and mitochondria for synergistic inhibition of cancer metastasis. International Journal of Pharmaceutics, 2021, 608, 121077.	5.2	9
51	Split bullets loaded nanoparticles for amplified immunotherapy. Journal of Controlled Release, 2022, 347, 199-210.	9.9	9
52	An in vitro investigation of a detachable fork-like structure as efficient nuclear-targeted sub-unit in A2780 cell cultures. International Journal of Pharmaceutics, 2016, 500, 100-109.	5.2	8
53	Active Targeting Nanoparticle Selfâ€Assembled from Cisplatinâ€Palbociclib Amphiphiles Ensures Optimal Drug Ratio for Combinatorial Chemotherapy. Advanced Therapeutics, 2021, 4, 2000261.	3.2	8
54	Complying with the physiological functions of Golgi apparatus for secretory exocytosis facilitated oral absorption of protein drugs. Journal of Materials Chemistry B, 2021, 9, 1707-1718.	5.8	6

#	Article	IF	Citations
55	Co-delivery of mitochondrial targeted lonidamine and PIN1 inhibitor ATRA by nanoparticulate systems for synergistic metastasis suppression. Nano Research, 2022, 15, 3376-3386.	10.4	6
56	Direct Cytoplasmic Delivery and Nuclear Targeting Delivery of HPMA-MT Conjugates in a Microtubules Dependent Fashion. Molecular Pharmaceutics, 2016, 13, 3069-3079.	4.6	5
57	Investigation of FcRnâ€Mediated Transepithelial Mechanisms for Oral Nanoparticle Delivery Systems. Advanced Therapeutics, 2021, 4, 2100145.	3.2	5
58	Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition. Journal of Materials Chemistry B, 2021, 9, 1336-1350.	5.8	5
59	Combination of mitochondria impairment and inflammation blockade to combat metastasis. Journal of Controlled Release, 2022, 341, 753-768.	9.9	5
60	Practical synthesis of immucillins BCX-1777 and BCX-4430. Organic Chemistry Frontiers, 2020, 7, 3675-3680.	4.5	4
61	A liposome-based combination strategy using doxorubicin and a PI3K inhibitor efficiently inhibits pre-metastatic initiation by acting on both tumor cells and tumor-associated macrophages. Nanoscale, 2022, 14, 4573-4587.	5.6	4
62	Enhanced nuclear delivery of H1-S6A, F8A peptide by NrTP6-modified polymeric platform. International Journal of Pharmaceutics, 2020, 580, 119224.	5.2	3
63	Asymmetric Total Synthesis of (+)-21-epi-Eburnamonine Via a Photocatalytic Radical Cascade Reaction. Natural Products and Bioprospecting, 2021, 11, 99-103.	4.3	3
64	Spatially targeting of tumor-associated macrophages and cancer cells for suppression of spontaneously metastatic tumor. Nano Research, 2022, 15, 3446-3457.	10.4	1
65	Beyond the Great Wall: Recent Advances in Molecular Pharmaceutics Research in China. Molecular Pharmaceutics, 2014, 11, 3231-3232.	4.6	0